These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 3082957)

  • 1. Effect of encainide and flecainide on chronic ectopic atrial tachycardia.
    Kunze KP; Kuck KH; Schlüter M; Bleifeld W
    J Am Coll Cardiol; 1986 May; 7(5):1121-6. PubMed ID: 3082957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Encainide versus flecainide for chronic atrial and junctional ectopic tachycardia.
    Kuck KH; Kunze KP; Schlüter M; Duckeck W
    Am J Cardiol; 1988 Dec; 62(19):37L-44L. PubMed ID: 3144166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL; Naccarelli GV; Berns E; Dougherty AH
    Am J Cardiol; 1988 Aug; 62(6):44D-55D. PubMed ID: 3136636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of incessant supraventricular tachycardia by intravenous and oral encainide.
    Brugada P; Abdollah H; Wellens HJ
    J Am Coll Cardiol; 1984 Dec; 4(6):1255-60. PubMed ID: 6438205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electrophysiology in assessing supraventricular arrhythmias: value of programmed stimulation in predicting and understanding efficacy of encainide.
    Wellens HJ; Brugada P
    Am J Cardiol; 1986 Aug; 58(5):37C-40C. PubMed ID: 3092617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias.
    Abdollah H; Brugada P; Green M; Wehr M; Wellens HJ
    Am J Cardiol; 1984 Sep; 54(6):544-9. PubMed ID: 6433688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encainide versus flecainide in the treatment of chronic resistant paroxysmal atrial tachyarrhythmias.
    Coumel P
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():579-84. PubMed ID: 2125836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation.
    Herre JM; Titus C; Oeff M; Eldar M; Franz MR; Griffin JC; Scheinman MM
    Ann Intern Med; 1990 Nov; 113(9):671-6. PubMed ID: 2121082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encainide for resistant supraventricular tachycardia in children: follow-up report.
    Strasburger JF; Smith RT; Moak JP; Gothing C; Garson A
    Am J Cardiol; 1988 Dec; 62(19):50L-54L. PubMed ID: 3144168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flecainide and encainide.
    Furlanello F; Vergara G; Bettini R; Mosna G; Gramegna L; Disertori M
    Eur Heart J; 1987 Mar; 8 Suppl A():33-40. PubMed ID: 3107989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of ectopic atrial arrhythmias and premature atrial complexes in adults with encainide.
    Pool PE; Quart BD
    Am J Cardiol; 1988 Dec; 62(19):60L-62L. PubMed ID: 2462340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol.
    Myerburg RJ; Kessler KM; Cox MM; Huikuri H; Terracall E; Interian A; Fernandez P; Castellanos A
    Circulation; 1989 Dec; 80(6):1571-9. PubMed ID: 2480856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation.
    Roden DM; Lee JT; Woosley RL; Echt DS
    Circulation; 1989 Nov; 80(5):1247-58. PubMed ID: 2805262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of tocainide, encainide, lorcainide and flecainide for supraventricular arrhythmias.
    Orning OM
    Eur Heart J; 1984 Sep; 5 Suppl B():81-6. PubMed ID: 6437821
    [No Abstract]   [Full Text] [Related]  

  • 15. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
    Fish FA; Gillette PC; Benson DW
    J Am Coll Cardiol; 1991 Aug; 18(2):356-65. PubMed ID: 1906902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antiarrhythmic drugs: tocainide, mexiletine, flecainide, encainide, and amiodarone.
    Kreeger RW; Hammill SC
    Mayo Clin Proc; 1987 Nov; 62(11):1033-50. PubMed ID: 3118116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia.
    Mason JW; Peters FA
    Circulation; 1981 Mar; 63(3):670-5. PubMed ID: 6780234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.
    Chase SL; Sloskey GE
    Clin Pharm; 1987 Nov; 6(11):839-50. PubMed ID: 3119276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic and electrophysiologic effects of encainide in patients with bundle branch block.
    Schwartz AB; Shapiro WA; Suave MJ; Shen E; Bhandari A; Morady F; Scheinman M
    Can J Cardiol; 1987 Mar; 3(2):75-82. PubMed ID: 3105850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of incessant supraventricular tachycardia treated with oral encainide.
    Brugada P; Wellens HJ
    Eur Heart J; 1987 Apr; 8(4):369-71. PubMed ID: 3111853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.